Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Ke Lan
CONTACT
Lead
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
CG-7321 is a novel oral small molecule CDK2 inhibitor with balanced CDK4/6/9 inhibition potency, being developed for the treatment of advanced solid tumors, being developed for the treatment of advanced solid tumors. Preclinical studies have demonstrated potent anti-tumor activity in breast cancer, ovarian cancer, and gastric cancer models. This Phase I study employs a dose escalation design to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of CG-7321. Part Ia evaluates CG-7321 monotherapy with dose levels of 2mg, 6mg, 12mg, 20mg, 30mg, 40mg, and 50mg BID in a 28-day cycle. Single dosing (Cycle 0) followed by multiple dosing (Cycle 1 onwards) will be evaluated. Part Ib evaluates CG-7321 in combination with fulvestrant or letrozole in HR+/HER2- advanced breast cancer patients. Dose expansion cohorts will further evaluate safety, PK, and preliminary efficacy at or near the RP2D in specific tumor types. Eligible subjects include patients with histologically/cytologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard therapy available, or who refuse standard treatment. Estimated enrollment: 44-66 subjects (Ia: 20-30; Ib: 24-36).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
